Gene: HRAS ×
Source: INFERRED ×
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
A 0.710 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894228
rs104894228
HRAS ; LRRC56
G 0.710 CausalMutation CLINVAR Hyperactive Ras in developmental disorders and cancer. 17384584

2007
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
T 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
A 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
G 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913233
rs121913233
HRAS ; LRRC56
G 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913233
rs121913233
HRAS ; LRRC56
A 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913496
rs121913496
HRAS ; LRRC56
A 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs28933406
rs28933406
HRAS ; LRRC56
C 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs121913233
rs121913233
HRAS ; LRRC56
C 0.700 CausalMutation CLINVAR Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. 23406027

2013
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894229
rs104894229
HRAS ; LRRC56
G 0.700 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009
dbSNP: rs104894230
rs104894230
HRAS ; LRRC56
A 0.700 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs121913233
rs121913233
HRAS ; LRRC56
C 0.700 CausalMutation CLINVAR Phase II trial of sorafenib in metastatic thyroid cancer. 19255327

2009
dbSNP: rs121913233
rs121913233
HRAS ; LRRC56
C 0.700 CausalMutation CLINVAR Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. 19773371

2009